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Alopecia areata affects 1%±2% of the population and
is hypothesized to be an autoimmune, organ speci®c
T-cell mediated reaction directed against the human
hair follicle. It is characterized by loss of hair in
patches (alopecia areata) with progression in some
individuals to total loss of scalp hair (alopecia totalis)
or to loss of all scalp and body hair (alopecia univer-
salis). The interleukin-1 receptor antagonist (IL-
1RN) gene was found to be associated with more
severe clinical outcome in several chronic in¯amma-
tory diseases, including alopecia areata. The IL-
1RN*2 allele was found to be associated with alope-
cia areata severity in a British case-control study. In
this paper, we analyzed alopecia areata probands in a
family-based sample (n = 131 parent±offspring trios)
to study the association between alleles of the IL-
1RN and various phenotypes of alopecia areata. In
considering all patients with any form of alopecia
areata, no association was found with IL-1RN. IL-
1RN*2 allele was not associated with alopecia totalis
and alopecia universalis. A borderline association was
observed between IL-1RN and patchy alopecia areata
but it was not statistically signi®cant (p = 0.06). We
also observed an association between IL1-RN*1 allele
and patchy alopecia areata (p = 0.045). Key words:
association tests/cytokines/genotypes/hair follicles. J Invest
Dermatol 118:335±337, 2002
A
lopecia areata (AA) is hypothesized to be an
autoimmune, organ speci®c T-cell mediated reaction
directed against the human hair follicle. It is
characterized by loss of hair in patches (AA), total
loss of scalp hair (alopecia totalis, AT), or total loss of
scalp and body hair (alopecia universalis, AU). AA occurs in 1%±2%
of the population, and has a strong hereditary component with
family history ranging from 10% to 25% in different studies
(Gollnick and Orfanos, 1990). Signi®cant associations in HLA class
II alleles (DR*5 and DQ*03) have been reported in case-control
(Duvic et al, 1995) and family-based studies (de Andrade et al, 1999;
Duvic et al, 2001). Twin studies have shown a concordance rate of
55% AA in identical twins but not in fraternal twins (Jackow et al,
1998). AA is widely regarded as an autoimmune disease where the
anagen hair follicles apparently become the target for an immune
cell attack.
The local production of pro-in¯ammatory cytokine interleukin
1 (IL-1) and its receptor antagonist (IL-1RA) is one of the major
determinants of an in¯ammatory response in the skin. Interleukin-
1a (IL-1a) found in high levels in keratinocytes can be released
following trauma, ultraviolet B irradiation, and local infection. It
has been previously shown that decreased levels of IL-1RA are
present in other in¯ammatory skin lesions including psoriatic
plaques (Kristensen et al, 1992). Therefore, IL-1 may play a role in
AA through a direct growth-inhibitory effect on hair follicles. The
gene for IL-1RA, also called IL-1RN, is located on the long arm of
chromosome 2 (2q14.2). The variable number of tandem repeats
(VNTR) in intron 2 of the gene IL-1RN has ®ve alleles,
comprising 2±6 repeats of an 86 bp sequence (Tarlow et al,
1994). The IL-1RN*2 allele has been found to be associated with
more severe clinical outcome in several chronic in¯ammatory
diseases, including systemic lupus erythematosus (Blakemore et al,
1994), ulcerative colitis (Mans®eld et al, 1994), and AA (Tarlow
et al, 1994; Cork et al, 1995).
The primary goal of this study was to evaluate whether speci®c
IL1-RN alleles are associated with AA in a family-based sample, as
previously published for sporadic cases.
MATERIALS AND METHODS
Data collection Cases were identi®ed from several dermatology clinics
at Texas Medical Center, Houston, TX, and through the web-site
http://www.mdanderson.org/departments/alopecia. DNA was extracted
from peripheral blood using standard protocols according to the
manufacturer's instructions (Stratagene, La Jolla, CA). A total of 143
families with 246 unaffected and 240 affected individuals were genotyped
for the IL-1RN gene (Duvic et al, 2001).
Polymerase chain reaction (PCR) analysis We have ampli®ed a
region from human genomic DNA in the IL-1RN gene using PCR
primers as described in Tarlow et al (1994): 5¢-TCCTGGTCT-
GCAGGTAA-3¢ and 5¢-CTCAGCAACACTCCTAT-3¢. PCR
conditions were as follows: a denaturing step at 94°C for 3 min, 40
cycles of 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min. The
®nal PCR products were analyzed on a 2.5% agarose gel and sized by
comparison to éX174 digested with Hinf-1 (Promega, Madison, WI)
and 100 bp DNA step ladder (New England BioLabs, Beverly, MA)
under ethidium bromide visualization.
Statistical analysis The occurrence of each allele occurring in the
family-based sample was expressed as a percentage of the total number of
alleles to give an allele frequency. The frequencies were estimated from
the pedigree data using the method proposed by Boehnke (1991) with
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the ILINK program of the LINKAGE package (Lathrop et al, 1984). The
rate of gene carriage is de®ned as the number of individuals carrying at
least one copy of a speci®c allele as a proportion of the total number of
individuals and was also calculated. c2 tests were performed on the
frequencies when appropriate. Family-based association tests between AA
cases and their parents were performed. From the 143 families, only 131
trios (one or both parents and one affected offspring) were eligible for
the analysis (parent and child sharing different heterozygous genotype).
The transmission disequilibrium test (TDT) was performed to evaluate
whether the IL-1RN gene is associated with AA (Spielman et al, 1993).
First, the c2 marginal homogeneity test was applied to evaluate whether
there is an association between IL-1RN and AA considering multiple
alleles at this gene. Second, the Ewen's c2 test was applied to evaluate
speci®c association from each IL-1RN allele and AA.
RESULTS
The allelic distributions for all affected probands (n = 240) and for
the phenotypic severity types of AA, AT, and AU are broken down
in Table I. Although there are ®ve different alleles of IL-1RN
(1, 410 bp; 2, 240 bp; 3, 500 bp; 4, 325 bp; 5, 595 bp), allele 5
was not present in these samples. The allele frequencies calculated
using either the entire family-based sample or the subset of the
unaffected members were not different from each other or from
Caucasian controls published in the literature (p > 0.10) (Tarlow et
al, 1994).
The frequency of allele 2 was 23.75% in the AA individuals
(p = 0.65) in comparison to a frequency of 25.20% in unaffected
family members. In 125 individuals characterized as having patchy
AA, the frequency of allele 2 was 21.20% compared to 24.07% and
27.27% in patients characterized as having AT or AU, respectively
(Table I). No statistically signi®cant difference was found between
these three groups (p = 0.15). Interestingly the frequency of allele 2
in all patients with any form of AA in our sample (23.75%) was
much lower than the frequency reported elsewhere (32.2%, Tarlow
et al, 1994). We also observed that this difference is statistically
signi®cant (p = 0.03).
The rate of gene carriage of the various IL-1RN alleles is shown
in Table II. The gene carriage of allele 2 was 36.8% for patchy AA,
44.44% for AT, and 48.86% for AU patients. Thus, there was an
increased gene carriage frequency of allele 2 in the more severe
forms of AA. These values were not as high as those published by
Tarlow et al of 44%, 66%, and 77%, respectively (Table II). The
observed allele 2 gene carriage rate in unaffected related individuals
(44.08%) was slightly higher than Tarlow's controls (41%). In
particular, the allele 2 gene carriage rate in all AA cases (36.8%) was
much lower than observed by Tarlow et al but it was not signi®cant
(p > 0.10).
The association test (TDT) was performed using parent±
offspring trios in which the control for the case was the unaffected
parent. No association was found between the IL-1RN gene and
AA as a trait in all affected individuals (p = 0.29). Nor was an
association found between any of the four alleles of the IL-1RN
gene and AA. Speci®cally, the p-value for allele 2 was 0.33.
Subsequently, TDT analyses were performed for all AA patients as
well as various AA subsets ± patchy AA and severe AA (AT and
AU) ± for each allele and for all alleles combined. No statistically
signi®cant associations were found for patchy AA (p = 0.06), AT
(p = 0.67), and AU (p = 0.88). The IL-1RN allele 2 was found not
to be associated with patchy AA (p = 0.07), with AT (p = 0.65), or
with AU (p = 1.00). We did observe a borderline statistically
signi®cant association, however, between IL-1RN allele 1 and
patchy AA (p = 0.045).
DISCUSSION
The genetic mechanisms of AA seem to be polygenic, where
several genes play a role in determining the disease susceptibility.
Genetic factors probably interact with environment factors, such as
infection, to trigger the onset of disease, whereas other factors may
determine how long the disease persists and how severe it becomes.
As in other autoimmune diseases, the HLA locus is a major disease
determinant (Spielman et al, 1993; Duvic et al, 1995, 2001; de
Andrade et al, 1999).
The severity of an in¯ammatory response to an environmental
trigger may also be determined by the balance of pro-in¯ammatory
and anti-in¯ammatory cytokines. IL-1a is a major pro-in¯amma-
tory cytokine in the epidermis. The potent pro-in¯ammatory
properties of IL-1a in the skin are balanced by the intracellular IL-
1RA, which is also present in large quantities in keratinocytes. It
seems likely that a relative de®ciency of the intracellular IL-1RA
could lead to the development of chronic in¯ammatory skin
diseases.
Our study con®rmed the ®ndings by Blakemore et al (1996) that
the four-repeat (IL1-RN*1) and two-repeat (IL-1RN*2) alleles are
the most commonly found alleles in human subjects. The other
alleles also occur at a combined frequency of less than 5%
(Blakemore et al, 1996). Despite the previous report of a strong
association between severity of AA and IL-1RN allele 2 (Tarlow
et al, 1994; Cork et al, 1995), our study failed to show the same
association among AA patients many of whom had a positive family
history of AA. Of note, the relative frequencies of each IL-1RN
allele were similar between the published control subjects, our
controls taken from unaffected family members, and the group of
affected plus unaffected individuals. Whereas Tarlow observed a
32.2% allelic frequency of allele 2, we found that only 23.75% of all
our AA subjects carried this allele (p = 0.03). This was the major
difference between the two groups of AA subjects.
We did not observe a signi®cant increase in the frequency of
allele 2 in our 240 AA subjects. Based on the former report by
Tarlow et al we would have expected an even greater increase in
allele 2 as some of the subjects in this study also were related to each
other. On the other hand, we did observe a new association
between IL-1RN allele 1 and patchy AA that was of borderline
statistical signi®cance.
There are several possibilities to explain the difference between
the results observed by Tarlow et al (1994) and this new cohort of
familial AA patients. First, the study designs were not equal. Tarlow
et al used a case-control design and ours is a family-based design in
Table I. Distribution of the IL-1RN allele frequencies from











1 72.92 75.20 72.22 69.89
2 23.75 21.20 24.07 27.27
3 2.08 2.40 1.85 1.70
4 1.25 1.20 1.85 1.14
Table II. Gene carriage rate of IL-1RN alleles among











1 91.46 92.00 96.63 92.05
2a 44.08 36.80 44.44 48.86
3 3.25 4.80 3.70 3.41
4 1.63 2.40 3.70 2.27
aPublished frequencies for gene carriage rate for allele 2: unaffected, 41%; patchy
AA, 44%; AT, 66%; AU, 77%. Gene carriage rate for alleles 1, 3, and 4 were not
presented (Tarlow et al, 1994).
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which cases were compared with their unaffected parents. Second,
the source of the patients was different (i.e. U.K. versus U.S.A.).
Nonetheless, our unaffected control relatives had the exact same
allelic frequencies as did Tarlow's unrelated control subjects and the
numbers of each were similar. Finally, the sample size of AA cases
in Tarlow's paper (n = 90) was smaller than ours (n = 240). For
example, he included only 18 AU patients compared to the 88
patients with AU in this study. The con®dence interval for his odds
ratio was 1.6±15.7, which is wide probably due to the small sample
size. If anything, our subjects should have ampli®ed the allelic
frequency results because they were related to the controls in family
studies. Thus, we conclude that the observed difference between
the results of Tarlow et al and our results is due to the presence of
different genes underlying the susceptibility to sporadic and familial
AA.
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